Fendler et al., 2023 - Google Patents
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0Fendler et al., 2023
View HTML- Document ID
- 5381885987400734007
- Author
- Fendler W
- Eiber M
- Beheshti M
- Bomanji J
- Calais J
- Ceci F
- Cho S
- Fanti S
- Giesel F
- Goffin K
- Haberkorn U
- Jacene H
- Koo P
- Kopka K
- Krause B
- Lindenberg L
- Marcus C
- Mottaghy F
- Oprea-Lager D
- Osborne J
- Piert M
- Rowe S
- Schöder H
- Wan S
- Wester H
- Hope T
- Herrmann K
- Publication year
- Publication venue
- European journal of nuclear medicine and molecular imaging
External Links
Snippet
Here we aim to provide updated guidance and standards for the indication, acquisition, and interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics are reported for a variety of available PSMA small radioligands. Different scenarios for the …
- 206010060862 Prostate cancer 0 title abstract description 85
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
- A61K51/1003—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody not used, see subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0493—Steroids, e.g. cholesterol, testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
- A61B6/50—Clinical applications
- A61B6/507—Clinical applications involving determination of haemodynamic parameters, e.g. perfusion CT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
- A61B6/48—Diagnostic techniques
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Detecting, measuring or recording for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/414—Evaluating particular organs or parts of the immune or lymphatic systems
- A61B5/415—Evaluating particular organs or parts of the immune or lymphatic systems the glands, e.g. tonsils, adenoids or thymus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fendler et al. | PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0 | |
| Fendler et al. | 68Ga-PSMA PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0 | |
| Lopci et al. | 68Ga-PSMA positron emission tomography/computerized tomography for primary diagnosis of prostate cancer in men with contraindications to or negative multiparametric magnetic resonance imaging: a prospective observational study | |
| Rauscher et al. | 68Ga-PSMA ligand PET/CT in patients with prostate cancer: how we review and report | |
| Wieser et al. | Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist 68Ga-RM2: preliminary results in patients with negative or inconclusive [18F] fluoroethylcholine-PET/CT | |
| Maurer et al. | Current use of PSMA–PET in prostate cancer management | |
| Cimitan et al. | [18F] fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients | |
| Jambor et al. | Prospective evaluation of 18F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate-to high-risk prostate cancer patients (FLUCIPRO trial) | |
| Schillaci et al. | Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy | |
| Liu et al. | SPECT/CT MIBG imaging is crucial in the follow-up of the patients with high-risk neuroblastoma | |
| Fuccio et al. | Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy | |
| Osborne et al. | A prospective pilot study of 89Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy | |
| Uprimny et al. | Early PET imaging with [68] Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence | |
| Wang et al. | The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer | |
| Suzuki et al. | Diagnostic performance and safety of NMK36 (trans-1-amino-3-[18F] fluorocyclobutanecarboxylic acid)-PET/CT in primary prostate cancer: multicenter Phase IIb clinical trial | |
| HK1223847A1 (en) | Methods of using spect/ct analysis for staging cancer | |
| Etchebehere et al. | Assessing the role of 18F-FDG PET and 18F-FDG PET/CT in the diagnosis of soft tissue musculoskeletal malignancies: a systematic review and meta-analysis | |
| Joraku et al. | Phase I/IIa PET imaging study with 89zirconium labeled anti-PSMA minibody for urological malignancies | |
| Hope et al. | SNMMI procedure standard/EANM practice guideline for fibroblast activation protein (FAP) PET | |
| Sodee et al. | Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer | |
| Geinitz et al. | Radiotherapy in prostate cancer: innovative techniques and current controversies | |
| Sekiyama et al. | Usefulness of diagnostic imaging in primary hyperparathyroidism | |
| Calderón et al. | One-day dual-tracer examination in neuroendocrine neoplasms: a real advantage of low activity LAFOV PET imaging | |
| CA2771316C (en) | Selective detection of bone metastases in renal clear cell carcinoma | |
| Muñoz-Iglesias et al. | PSMA PET/CT quick procedure guide |